Lv2
188 积分 2025-06-11 加入
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
15天前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
15天前
已完结
Long-term outcome and quality of life in patients with iliac vein compression syndrome after endovascular treatment
16天前
已完结
Combined transjugular/percutaneous intrahepatic portosystemic shunts (cTIPS) for cavernous transformation of the portal vein after conventional transjugular approach TIPS failure
16天前
已完结
Association of nonmalignant portal vein thrombosis and clinical outcomes in patients with cirrhosis and acute variceal bleeding: a multicenter observational study
16天前
已完结
Endovascular Treatment of an Unusual Membranous Obstruction of the Inferior Vena Cava in Budd-Chiari Syndrome Complicated by Mural Portal Vein Thrombosis
16天前
已完结
Peripheral Blood Plasminogen Activator Inhibitor 1 and Tissue-Type Plasminogen Activator-Inhibitor Complex Levels for the Diagnosis and Prediction Value of Venous Thromboembolism in Malignant Tumors
17天前
已完结
Platelet Parameters as Biomarkers for Thrombosis Risk in Cancer: A Systematic Review and Meta-analysis
17天前
已完结
Circulating Blood Biomarkers and Risk of Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis
17天前
已完结
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment
1个月前
已完结
皖公网安备34019202002308
